Clinical Trials Browser

Phase 2 × Prostatic Neoplasms, Castration-Resistant × Pluvicto × Clear all

NCT07047118 2026-05-01

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 2 Active not recruiting

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant